HCM
BIIB icon

Highbridge Capital Management’s Biogen BIIB Stock Holding History

Highbridge Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,000
Closed -$290K – 513
2018
Q2 		$290K Sell
1,000
-1,100
-52% -$309K 0.01% 715
2018
Q1 		$574K Sell
2,100
-3,400
-62% -$1.06M 0.01% 649
2017
Q4 		$1.76M Buy
5,500
+2,300
+72% +$738K 0.03% 418
2017
Q3 		$999K Buy
+3,200
New +$948K 0.02% 597
2013
Q3 		– Sell
-9,500
Closed -$2.04M – 1271
2013
Q2 		$2.04M Buy
+9,500
New +$2.03M 0.02% 486

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's BIIB Position: Q4 2018 in Review

Highbridge Capital Management sold out of Biogen (BIIB) in Q4 2018, closing a stake of 7,491 shares — an estimated $2.65M sold.

Highbridge Capital Management first reported a position in BIIB in Q2 2013 and held it in 15 quarters. The position peaked at $49M in Q4 2014. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • Highbridge Capital Management reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 7,491 Biogen shares in Q4 2018, an estimated $2.65M.
  • Highbridge Capital Management first reported a position in Biogen in Q2 2013 and held it in 15 quarters.
  • Highbridge Capital Management's Biogen position peaked at $49M in Q4 2014.
  • 1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.